Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
Multicenter, Double Blind, Metronidazole Controlled, Dose Range Finding Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
Sponsor: Romark Laboratories L.C.
Listed as NCT00417872, this PHASE2 trial focuses on Clostridium Difficile and remains completed. Sponsored by Romark Laboratories L.C., it has been updated 4 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2017 — Jan 2021 [monthly]
Completed PHASE2
First recorded
Jan 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Romark Laboratories L.C.
For direct contact, visit the study record on ClinicalTrials.gov .